Want to see HK:2160 full AI Analyst Report?
2160 Stock Chart & Stats
HK$1.25
HK$0.04(6.15%)
At close: 4:00 PM EST
HK$1.25
HK$0.04(6.15%)
Day’s Range― - ―
52-Week RangeHK$0.93 - HK$7.95
Previous CloseN/A
Volume546.00K
Average Volume (3M)601.00K
Market Cap
HK$1.63B
Enterprise ValueHK$970.39
Total Cash (Recent Filing)HK$1.38B
Total Debt (Recent Filing)HK$258.36M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding1,273,311,400
10 Day Avg. Volume0
30 Day Avg. Volume601,004
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.49
Price to Sales (P/S)6.71
P/FCF Ratio-10.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)HK$300.12M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSteady top-line expansion indicates continued demand for the company’s cardiovascular intervention products. Sustained growth can improve operating leverage over time, broaden hospital and distributor adoption, and provide a foundation for eventual profitability.
Solid Gross MarginA gross margin near 55% suggests the product portfolio retains meaningful economics before operating expenses. This provides room to fund research, commercialization, training, and manufacturing investments while supporting a potential path toward improved earnings.
Recurring Procedure-Linked DemandSales tied to cardiovascular procedures and single-use consumables can create repeat demand as hospitals perform ongoing interventions. This usage-based model may support customer retention and more durable revenue than one-time equipment sales.
Bears Say
Persistent UnprofitabilityRevenue growth has not yet translated into sustainable earnings, and losses widened versus 2024. Continued unprofitability limits internally generated capital, increases dependence on financing, and raises execution risk as the company scales its commercial operations.
Negative Cash GenerationThe company remains unable to consistently self-fund its operations and investment needs. Negative free cash flow is particularly concerning alongside ongoing losses and higher leverage, because prolonged cash burn could require additional borrowing or equity financing.
Sharp Leverage IncreaseThe sharp increase in leverage materially reduces financial flexibility while the business is loss-making. Higher debt can increase refinancing exposure, constrain investment capacity, and make future cash shortfalls more difficult to manage without external funding.
MicroPort CardioFlow Medtech Corp. News
2160 FAQ
What was MicroPort CardioFlow Medtech Corp.’s price range in the past 12 months?
MicroPort CardioFlow Medtech Corp. lowest stock price was HK$0.93 and its highest was HK$7.95 in the past 12 months.
What is MicroPort CardioFlow Medtech Corp.’s market cap?
MicroPort CardioFlow Medtech Corp.’s market cap is HK$1.63B.
When is MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date?
MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date is Mar 30, 2027 which is in 189 days.
How were MicroPort CardioFlow Medtech Corp.’s earnings last quarter?
MicroPort CardioFlow Medtech Corp. released its earnings results on Aug 28, 2025. The company reported -HK$0.525 earnings per share for the quarter.
Is MicroPort CardioFlow Medtech Corp. overvalued?
According to Wall Street analysts MicroPort CardioFlow Medtech Corp.’s price is currently Overvalued.
Does MicroPort CardioFlow Medtech Corp. pay dividends?
MicroPort CardioFlow Medtech Corp. does not currently pay dividends.
What is MicroPort CardioFlow Medtech Corp.’s EPS estimate?
MicroPort CardioFlow Medtech Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MicroPort CardioFlow Medtech Corp. have?
MicroPort CardioFlow Medtech Corp. has 1,273,311,400 shares outstanding.
What happened to MicroPort CardioFlow Medtech Corp.’s price movement after its last earnings report?
MicroPort CardioFlow Medtech Corp. reported an EPS of -HK$0.525 in its last earnings report. Following the earnings report the stock price went up 1.128%.
Which hedge fund is a major shareholder of MicroPort CardioFlow Medtech Corp.?
Currently, no hedge funds are holding shares in HK:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroPort CardioFlow Medtech Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
Company Description
MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily within the People's Republic of China, its innovative product line includes the Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, specifically engineered to treat aortic, mitral, tricuspid, and surgical valve disorders. The company also supplies a range of essential procedural accessories. MicroPort CardioFlow Medtech, which commenced operations in 2010, maintains its corporate headquarters in Shanghai, China.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―